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The number of patients with end-stage renal disease (ESRD) is rising very rapidly as the number of elderly and patients 
with diabetes increases in Korea. ESRD Registry Committee of the Korean Society of Nephrology (KSN) collected dialysis 
therapy data in Korea through an online registry program on the KSN website. The status of renal replacement therapy in 
Korea at the end of 2009 was as follows. First, total number of patients with ESRD was 56,396 (hemodialysis [HD], 37,391; 
peritoneal dialysis [PD], 7,618; functioning kidney transplant [KT], 11,387). The prevalence of ESRD was 1,113.6 patients 
per million population (PMP). Proportion of patients undergoing renal replacement therapy was 66.3% with HD, 13.5% with 
PD, and 20.2% with KT. Second, a total of 8,906 (HD, 6,540; PD, 1,125; KT, 1,241; incidence rate of 175.9 PMP) patients 
developed ESRD in 2009. Third, the most common primary causes of ESRD were diabetic nephropathy (45.4%), hyper-
tensive nephrosclerosis (18.3%), and chronic glomerulonephritis (11.1%). Fourth, mean urea reduction rate was 67.5% and 
73.8% in male and female patients, respectively, undergoing HD. Mean Kt/V was 1.38 in male patients and 1.65 in female 
patients. Fifth, the overall 5-year survival rate of male patients undergoing dialysis was 65.4% and that of female patients 
was 67.4%. (Korean J Intern Med 2011;26:123-131)
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INTRODUCTION
A patient registry and a statistical evaluation of patients 
with end-stage renal disease (ESRD) is useful to estimate 
the number and distribution of patients for targeted 
therapy by groups specializing in dialysis (Korean Society 
of Nephrology; KSN). They can be applied to clarify the 
characteristics of ESRD and dialysis therapy, as well as 
the complications or results based on scientific evidence, 
to improve the quality of dialysis therapy and provide 
socioeconomic health administration information for a 
future health plan. Based on the growth of the elderly 
population and patients with diabetes, the prevalence of 
ESRD and the number of hemodialysis (HD) machines 
is increasing very rapidly in Korea compared to other 
developed counties [1,2]. 
The first Korean nationwide registry of patients with 
ESRD was reported by Professor Byung Suk Min in 1977. 
The KSN launched an official registry program as “Insan 
Prof. Min Memorial Renal Replacement Therapy Registry” 
in 1985 after his death by North Korean terrorists. 
Data collection
The KSN ESRD Registry Committee has collected data 
about dialysis centers and patients through an online 
registry program at the KSN internet website (http://www.
ksn.or.kr) since 2001. This program also has a graphic 
evaluation function for dialysis adequacy (Kt/V, nPCR) 
and a peritoneal equilibrium test. For security of the 
patient’s personal information, the program can be opened 
only by designated dialysis staff with a hospital code and 
password. Information about dialysis centers that did not 
respond was collected through paper mail questionnaires.
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Figure 1. Prevalence and incidence of ESRD in Korea. (A) Numbers of renal replacement therapy patients at the end of each year. (B) 
New renal replacement therapy patients by year. (C) Three major causes of ESRD. ESRD, end-stage renal disease; HD, hemodialysis; KT, 
kidney transplant; PD, peritoneal dialysis; CGN, chronic glomerulonephritis; DM, diabetes mellitus; HTN, hypertensive nephrosclerosis.
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Table 1. Causes of end-stage renal disease in new patients
Causes 1992 1994 1996 1998 2000 2002 2004 2006 2007 2008 2009
a
Chronic glomerulonephritis 25.3 25.5 21.6 17.9 14 13.9 12.5 13 11.6 12.1 11.1
Not histologically confirmed 19.7 20.4 16.7 13.6 10.6 10 8.6 9 8.3 8.2 7.5
Histologically confirmed 5.6 5 4.9 4.3 3.4 3.9 3.9 3.9 3.3 3.8 3.6
Diabetic nelphropathy 19.5 26.1 30.8 38.9 40.7 40.7 43.4 42.3 44.9 41.9 45.4
Hypertensive nephrosclerosis 15.4 20.8 18.3 17.8 16.6 16 16.2 16.9 17.2 18.7 18.3
Cystic kidney disease 2.1 2.2 1.8 1.7 2.2 1.6 1.4 1.7 1.7 1.7 1.8
Renal tuberculosis 1.1 1.5 1.2 0.5 0.4 0.5 0.3 0.3 0.3 0.2 0.2
Pyelo/inerstitial nephritis 1.3 1.1 0.7 1 0.8 0.6 0.6 0.6 0.5 0.5 0.5
Drugs or nephrotoxic agents 1.3 0.1 0.6 0.3 0.3 0.4 0.2 0.3 0.2 0.3 0.3
Lupus nephritis 0.8 0.7 1 0.5 0.9 0.8 0.6 0.6 0.6 0.6 0.6
Gouty nephropathy 0.7 0.7 0.6 0.5 0.7 0.4 0.5 0.3 0.3 0.3 0.3
Hereditary nephropathy 0.3 0.7 0.4 0.2 0.1 0.2 0.3 0.3 0.2 0.3 0.2
Kidney tumor 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.2 0.1 0.2 0.2
Other 0.4 2.7 2.8 3.9 3 5.6 5.9 6 5.1 5.8 5.2
Uncertain 28.6 17.8 15.9 16.6 20.2 19 17.8 17.5 17.2 17.6 16.0
Values are presented as percent (%).
an = 9,528.Jin DC. Current dialysis therapy in Korea    125
DATA ON DIALYSIS THERAPY IN KOREA
Prevalence and incidence of ESRD in Korea
A total of 37,391 patients with ESRD underwent 
maintenance HD and 7,618 underwent peritoneal dialysis 
(PD), whereas 11,387 had a functioning kidney transplant 
(KT). Overall, 56,396 patients with ESRD were in Korea 
at the end of 2009. The prevalence per million population 
(PMP) was 738.3 undergoing HD, 150.4 undergoing PD, 
and 224.8 KTs. The overall PMP was 1113.6 with ESRD 
(Fig. 1A). This prevalence rate is similar to that of most 
European countries but about half of that in the United 
States and one-third of that in Japan, according to 
international data from annual US renal data reports [2-4]. 
The increasing rate of prevalence per year was about 12% 
during 2000-2009.
A total of 8,906 patients (175.9 PMP) underwent new 
renal replacement therapy in 2009 (Fig. 1B). A total of 
6,540 (129.1 PMP) new patients with ESRD underwent 
HD, 1,125 (22.2 PMP) underwent PD, and 1,241 (24.5 
PMP) KTs were performed. The number of new patients 
undergoing PD has been decreasing since 2007 but those 
of HD and KT has increased, which is similar to what 
occurred in the United States [2]. 
The most common causes of ESRD in new patients 
were diabetic nephropathy, hypertensive nephrosclerosis, 
and chronic glomerulonephritis (45.4%, 18.3%, 11.1%, 
respectively; Table 1). Among these three underlying 
diseases, diabetic nephropathy increased very rapidly 
during 1990-2000 (Fig. 1C). The proportion of Korean 
patients with ESRD and diabetic nephropathy was higher 
compared to some Asian countries and the United States 
[2].
Renal replacement therapy modalities
In 2009, approximately 73% of new patients with ESRD 
started renal replacement therapy with HD, and about 
13% patients started PD; the prevalence rates of patients 
undergoing HD, PD, and KT were 66.3%, 13.5%, and 
20.2%, respectively (Fig. 2A).
The number of HD centers and HD machines is also 
increasing rapidly in Korea. In total, 614 HD centers and 
13,874 HD machines were available in Korea at the end of 
2009 (Fig. 2B). The ratio of machines per center was 22.6 
and that of patients per machine was 2.7.
About one-third of patients underwent maintenance HD 
at a university hospital in the late 1990s, whereas about 
half of patients currently undergo HD at private dialysis 
clinics (Fig. 2C).
A distribution analysis of patients with ESRD according 
to life zone in Korea showed that about half of patients 
undergoing HD and more than half of patients undergoing 
PD lived in the capital area (Fig. 2D).
Dialysis patient demographics
The gender ratio of patients undergoing HD therapy was 
57.6% male vs. 42.4% female, while it was 55.6% male vs. 
44.2% females for those undergoing PD therapy.
The mean age of patients undergoing dialysis was 57.3 
± 13.8 years. The age distribution of patients undergoing 
dialysis revealed two peaks: one at age 50 years and 
another at age 65 (Fig. 3A), indicating the occurrence of 
at least two different disease groups. The age distribution 
according to year since 1986 showed that peak age shifted 
toward older age, and that the current peak age includes 
patients in their 60s (Fig. 3B). Elderly patients (> 65 years) 
undergoing dialysis increased to 33.8% of the overall 
number of patients undergoing dialysis in 2009.
The age distribution according to underlying disease 
showed that the peak age for chronic glomerulonephritis 
was 51.3 years and that for diabetic nephropathy was 60.6 
years (Fig. 3C).
About 43% of patients undergoing HD and 40% of 
patients undergoing PD were on dialysis for more than 
5 years, which was an increase from 30% and 14%, 
respectively, since 2001 (Fig. 3D). 
About 51% of nondiabetic patients undergoing HD were 
on dialysis for more than 5 years, but only about 29% of 
patients with diabetes undergoing HD were on dialysis for 
more than 5 years. Moreover, about 45% of nondiabetic 
patients undergoing PD were on dialysis for over 5 years, 
but about only 32% of patients with diabetes undergoing 
PD were on dialysis for more than 5 years.
The mean body mass index (BMI) of patients undergoing 
HD was 21.8 ± 3.2 kg/m
2 and that of patients undergoing 
PD was 23.4 ± 3.6 kg/m
2 (Fig. 3E). Of patients undergoing 
HD, the mean BMI of those with diabetes was 22.2 ± 3.3 
kg/m
2 and that of nondiabetic patients was 21.5 ± 3.2 kg/
m
2.
The mean blood pressure of patients undergoing HD 
was 102 ± 12.4 mm Hg and that of patients undergoing 
PD was 99.8 ± 12.8 mm Hg (Fig. 3F), but the pulse 
pressure of patients undergoing HD was much higher 
than that of patients undergoing PD (63.4 vs. 53.0 mm Hg, 
respectively; Fig. 3G).  126    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
Erythropoietin therapy, HD, and PD therapy 
characteristics
In 2009, the mean hematocrit of patients undergoing HD 
was 31.5% and that of patients undergoing PD was 30.2%, 
which were reversed from 2001 figures. Theoretically, 
patients undergoing PD had a lower prevalence of anemia, 
but recently developed erythropoietin therapy has 
increased hematocrits in patients undergoing HD. This 
rapid increase in hematocrit from 2004 to 2005 was due to 
an increase in the erythropoietin therapy reimbursement 
level (Fig. 4A). This therapeutic result is shown quite 
clearly in Fig. 4B, in which 31% of patients undergoing HD 
were injected with 8,000 units or more erythropoietin per 
week, whereas only 15% of patients undergoing PD were 
injected with 8,000 units or more erythropoietin per week 
(20% of patients undergoing PD were not administered 
erythropoietin).
Most (85%) HD centers use polysulfone dialyzers, whereas 
about 5% of centers reuse dialyzers. Hemodiafiltration 
therapy was available in 36% of dialysis centers in Korea (Fig. 
4C).
Gender differences in the urea reduction ratio are shown 
in Fig. 4D. The urea reduction ratio in male patients 
undergoing HD was 67.5% and that in females undergoing 
HD was 73.8%. This difference was due to the use of the 
same dialysis dose on different body masses. The overall 
mean urea reduction ratio was 70.2 ± 7.4%.
The normalized protein catabolic rate and Kt/V were 
0.977 ± 0.29 and 1.946 ± 0.37, respectively, which were 
both higher in female patients than male patients (Fig. 
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Figure 2. Renal replacement therapy modalities. (A) Proportion of renal replacement modalities. Annual prevalence and incidence in 
2009. (B) Number of hemodialysis centers and hemodialysis machines. (C) Percent distribution of patients undergoing hemodialysis 
according to the dialysis center classification. (D)  Distribution of patients undergoing dialysis based on their life zone in Korea. KT, 
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Figure 3. Dialysis patient demographics. (A) Age distribution of pa-
tients undergoing dialysis according to dialysis modality.  (B) Age dis-
tribution of patients undergoing dialysis. Note that the peak age has 
shifted toward an older age. (C) Age distribution of patients undergo-
ing dialysis according to underlying diseases: patients with diabetes 
mellitus (DM), hypertensive nephrosclerosis (HTN), and glomerulo-
nephritis (GN). Note the difference in peak age between GN and DM. 
(D) Duration of maintenance hemodialysis and peritoneal dialysis. 
Percentage of estimated patient numbers by year. (E) Body mass 
index (BMI) distribution in patients undergoing hemodialysis (HD) 
and peritoneal dialysis (PD). (F) Distribution of mean blood pressure 
(MBP) in patients undergoing HD and PD. The blood pressure (BP) in 
patients undergoing HD was higher than that of patients undergoing 
PD. (G) Systolic and diastolic BP with pulse pressure in patients un-
dergoing HD and PD. Note the difference in pulse pressure between 
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Figure 4. Erythropoietin therapy, hemodialysis (HD) and peritoneal dialysis (PD) therapy characteristics. (A) Changes in hematocrit (%) 
in patients undergoing dialysis: HD vs. PD. Note the increase in the hematocrit of patients undergoing HD. (B) Percent distribution of 
erythropoietin (EPO) doses prescribed for patients undergoing HD and PD. (C) Currently using HD membrane and dialysis membrane 
reuse and percentage of hemodiafiltration (HDF) in private clinics. (D) Distribution of the urea reduction ratio (URR) in patients under-
going HD. Note the difference between males and females. (E) Dialysis adequacy parameters (nPCR and Kt/V) of patients undergoing 
HD. (F) Dialysis adequacy parameters (Kt/V) for patients with diabetes mellitus (DM) and nonDM who were undergoing HD. (G) An-
nual changes in dialysis adequacy parameters for patients undergoing HD. (H) Percent distribution of peritoneal dialysis type and doses 
(2009, n = 2,836). CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis. Jin DC. Current dialysis therapy in Korea    129
4E). The Kt/V was higher in nondiabetic patients than 
patients with diabetes probably due to the quality of 
dialysis vascular-access points (Fig. 4F).
The quality of HD therapy has improved annually (Fig. 
4G), but the protein catabolic rate has decreased recently, 
probably due to the increase in the number of elderly 
patients undergoing dialysis.
The percentage of patients using automated PD rose to 
18% in 2009, but the overall PD dose (dialysate amount) 
did not increase (Fig. 4H).
Morbidity, causes of death, and survival rates of 
patients undergoing dialysis 
The most common complication (51%) in patients 
Table 2. Comorbidities of patients undergoing dialysis in 2009
HD patients, % PD patients, %
Cardiac 14.6 15.9
Coronary artery disease 6.0 7.8
Congestive heart failure 4.2 5.8
Pericardial effusion 0.7 1.0
Arrythmia 3.7 1.3
Vascular 51.0 55.7
Cerebrovascular accident 4.3 1.5
Hypertension               44.7              53.7
Other vascular disease 2.0 0.5
Infection 5.2 9.1
Pneumonia 1.3 1.8
Tuberculosis 0.6 0.0
Peritonitis 0.5 5.3
Herpes zoster 0.3 0.5
Other infection 2.4 1.5
Liver disease 8.2 4.0
Hepatitis B 5.0 2.3
Hepatitis C 2.6 0.8
Congestive liver 0.0 0.0
Hemochromatosis 0.1 0.0
Other liver diseases 0.4 1.0
Gastrointestinal 10.1 9.3
Gastric ulcer 2.5 4.8
Duodenal ulcer 0.3 0.5
Other gastrointestinal diseases 7.3 4.0
Miscellaneous 10.9 6.0
Malnutrition (Alb < 2.5 g/dL) 0.5 0.8
Malignancy 1.7 0.8
Hypertensive retinopathy 2.1 2.5
Uremic dermatitis 2.4 0.3
Uremic neuritis 1.9 0.8
Uremic dementia 0.6 0.0
Uremic ascites/pleural effusion 0.9 0.8
Osteodystrophy 0.9 0.3
Reported patients number: hemodialysis  = 4,120, perioneal dialysis = 397.
HD, hemodialysis; PD, perioneal dialysis.130    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
Figure 6. Kidney transplantation and dialysis costs. (A) Annual number of kidney transplantations (KTs) in Korea (including data from 
the Korean Network for Organ Sharing). 
aSurviving number of patients waiting for KTs at the end of each year. (B) Annual number of 
patients with chronic kidney disease (International disease code: N18) and medical costs. Data from the National Health Insurance Cor-
poration. 
8,488
7,641 6,695
5,672 4,910
4,309 3,878
3,417 2,904
2,309
198247
357
565613680
905
720685
905919928994
1,085
682
791739808853762
935 928
1,144
1241
100172234310
125 10170124167173263280
481495
10489 88 12513510912185 71 80 73 65 57 53 33 34 29 27 26 22 25 24 28 28
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,250
1,000
750
500
250
0
86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09
N
o
.
 
o
f
 
K
T
P
a
t
i
e
n
t
s
 
n
o
.
KT waiting no.a
Transplant no. / 1,000 dialysis pts
Transplant no.
CAD transplant no.
Year
A
100,000
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
10,000
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
P
a
t
i
e
n
t
 
n
o
.
C
o
s
t
 
 
(
0
.
1
 
b
i
l
l
i
o
n
 
w
o
n
)
Male Female Cost
2001 2002 2003 2004 2005 2006 2007 2008
Year
B
Figure 5. Morbidity, causes of death and survival rates of patients undergoing dialysis. (A) Comparison of the causes of death for 
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undergoing HD was vascular disease, including 
hypertension, cerebrovascular accidents, and other 
vascular diseases (Table 2). Approximately 56% of patients 
undergoing PD had vascular disease, and a higher infection 
complication rate was evident in patients undergoing PD 
(9.1%) compared to those undergoing HD (5.2%). 
The causes of death in patients undergoing dialysis 
were cardiac, infection, vascular disease, in that order, 
and one-quarter of the causes of death were unknown or 
miscellaneous (Fig. 5A). Some year-to-year variation was 
observed due to limitations in the death reports. 
The overall survival rates for patients undergoing 
dialysis were 94% after 1 year and 66% after 5 years of 
dialysis (Fig. 5B). These survival rates were higher than 
those in the United States and Japan [2,3] but were 
calculated from registered patients undergoing dialysis 
from 2001. That registry, however, includes only about 
two-thirds of the total number of patients undergoing 
dialysis in Korea because the registry included voluntary 
enrollment by KSN members. 
The 5-year survival rate in patients undergoing HD 
was higher than that of patients undergoing PD (67.4% 
vs. 59.4%, respectively; Fig. 5C) and that for nondiabetic 
patients was higher than that of patients with diabetes 
(75.8% vs. 55.9%, respectively; Fig. 5D).
KT and dialysis costs
In 2009, KT was performed in 1,241 cases, which rose 
with the increase in the number of available cadaver 
donors (Fig. 6A). The KT rate was 28 cases per 1,000 
patients undergoing dialysis, which was below the world 
average [2]. However, the number of patients waiting for 
KTs increased more sharply; 8,488 surviving patients 
undergoing dialysis were enrolled on the Korean Network 
of Organ Sharing waiting list at the end of 2009.
Based on the increased number of patients undergoing 
dialysis, overall dialysis cost in Korea has rapidly 
increased to 820 billion Korean won in 2009 (National 
Health Insurance Corporation; 1 US dollar = 1,100 Korean 
won; Fig. 6B). 
CONCLUSIONS
Because of the increase in the elderly population and the 
number of patients with diabetes, the number of patients 
with ESRD has increased rapidly to 1,114 PMP at the end 
of 2009. A high proportion (45%) of patients with diabetes 
and ESRD and a decrease in the proportion undergoing 
PD was recently observed. The adequacy of dialysis and 
anemia therapy has been improving steadily in Korea. 
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